Manage Your Liver
Q:

New research finding: New hepatitis C antiviral drugs increase the risk of liver cancer

New research finding: New hepatitis C antiviral drugs increase the risk of liver cancer
A:

A study published in the International Liver Congress in 2016 [1] came up with a shocking and unexpected result: Patients with hepatitis c and cirrhosis who use direct antiviral agents (DAA) may begin to develop liver cancer within 2 weeks. Leading researcher Stefano Brillianti, MD stated “The hypothesis is that immune surveillance may be reduced too rapidly,” and “You have an immediate drop in viremia, but also attenuation of inflammation.”

 

The study indicated that patients with a history of hepatocellular carcinoma (liver cancer) have the highest risk of developing tumor after receiving direct-acting antiviral therapy, in addition, the progression is very fast. "Patients with previous hepatocellular carcinoma are, of course, at risk of recurrence anyway," Dr Brillianti said. ”A 30% rate over 3 years from initial surgery or ablation is normal. What was surprising to us was that we were observing 4 cm lesions after 12 weeks." [2]

 

Another research conducted by the University of Barcelona found that out of 58 hepatitis C patients with a history of hepatocellular carcinoma (with complete radiologic response), 55 were cirrhotic before starting direct-acting antiviral therapy. After a median follow-up of 5.7 months, the rate of tumor recurrence was 27.6%, with a median time to recurrence of 3.5 months. This research echoes with the previously mentioned, and suggests that patients with hepatitis C should be closely monitored after treatment with direct-acting antivirals. [3]

 

Stefano Brillanti, MD, went on to say, "This (liver cancer) is a different cancer  than elsewhere in oncology — it is a cancer within an advanced chronic disease — so the prognosis, the life expectancy, is related not only to the liver cancer but also to the liver disease and liver function,”. He added, "If you don't treat these patients and ameliorate their liver function, and if hepatocellular carcinoma occurs, you have no chance of curing them. But if you ameliorate liver function and they develop hepatocellular carcinoma, you can cure it better because their improved liver function will allow an ablation.”

 

These two latest research studies once again prove that is it vital to stop inflammation in the liver, and to ensure normal liver function. Whether it is before or after treatment, both hepatitis C patients and patients with hepatocellular carcinoma history should set this as their main objective. Otherwise, even if the virus is successfully removed from the body, normal liver function cannot be guaranteed.

Disclaimer:
  • * All research and clinical data should be used as reference purposes only, results may vary.
Tags:
Hepatitis CLiver CancerHep CAntiviralDDAsDirect acting antiviral treatment
Related Questions
A:
Cancer is a leading cause of morbidity and mortality in the United States and results in a high economic burden. A recent research published by The JAMA Network has reveal that cancer mortality declined overall in the United States between 1980 and 2014. And the number of deaths for nearly all forms of cancer has decreased significantly, but not for liver cancer, kidney cancer and non-Hodgkin lymphoma (NHL) cancer.   Deaths due to NHL and kidney cancer remained the sa
A:
ALT (Alanine Aminotransferase / SGPT) is an enzyme that is mainly found in liver cells. The level of ALT in our bloodstream is the primary indicator of liver health. Multiple studies have demonstrated that the presence of an elevated ALT level is associated with increased liver-related mortality.   New normal ALT level issued The American College of Gastroenterology (ACG) recently issued a new Practice Guideline that aims to offer a framewor
Hit Questions
A:
Cancer is a leading cause of morbidity and mortality in the United States and results in a high economic burden. A recent research published by The JAMA Network has reveal that cancer mortality declined overall in the United States between 1980 and 2014. And the number of deaths for nearly all forms of cancer has decreased significantly, but not for liver cancer, kidney cancer and non-Hodgkin lymphoma (NHL) cancer.   Deaths due to NHL and kidney cancer remained the sa
A:
Recent research by the University of Edinburgh have gained new insight into how common painkiller paracetamol causes liver damage. The research studied the impact of paracetamol on liver cells in human and mouse tissue.   Toxicity liver damage is currently the leading cause of acute liver failure in the Western world. Long term or excessive use of paracetamol can damage the liver by harming vital structural connections between cells. One of the common result of toxici
A:
Fatty liver is on the rise and it is quickly becoming one of the most worrying disease in developed countries, a condition that most Americans have never heard of and now experts say as many as one in three of us may be at risk. Fatty liver disease is a gradual killer which often shows no symptoms until it develops into a much server problem like: cirrhosis - a condition that could lead to liver cancer or death.   Douglas Denham is medical director at Clinical Trials
A:
ALT (Alanine Aminotransferase / SGPT) is an enzyme that is mainly found in liver cells. The level of ALT in our bloodstream is the primary indicator of liver health. Multiple studies have demonstrated that the presence of an elevated ALT level is associated with increased liver-related mortality.   New normal ALT level issued The American College of Gastroenterology (ACG) recently issued a new Practice Guideline that aims to offer a framewor
YHK Liver Therapy
Your Liver
Protection

starts here.
Buy YHK
Have Questions?
Sumbit your question to us for profeessional answers!
Looking for help? Ask our customer support team!
Contact Us